Contractor
MELINTA THERAPEUTICS, LLC
PARSIPPANY, NJ
- UEI
- H8K6F2A4KD49
- Parent UEI
- H8K6F2A4KD49
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$47,521,2481
Awards
2
Agencies served
2
Active from Jul 6, 2023 to Sep 18, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75A50123C00022 ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | Department of Health and Human Services | DC | Jul 6, 2023 | $47,521,248 |
| 36F79724D0178 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD | Department of Veterans Affairs | — | Aug 13, 2024 | — |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier H8K6F2A4KD49, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Oct 21, 2026.